Abstract
Bevacizumab (Avastin) is a recently developed monoclonal antibody, which targets the vascular endothelial growth factor signaling pathway, and is currently used in combination with cytotoxic agents as first-line or second-line therapy for patients with metastatic colon cancer. Hypertension is a known risk factor associated with the use of bevacizumab. In this report, we describe the incidence, etiology, and management of patients with this complication.
Original language | English (US) |
---|---|
Pages (from-to) | S22-S24 |
Journal | Anti-Cancer Drugs |
Volume | 20 |
Issue number | SPEC. ISS. 2 |
DOIs | |
State | Published - May 2009 |
Keywords
- Avastin
- Metastatic colon cancer
- VEGF
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)
- Cancer Research